Israeli - Kiebrania - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - temozolomide - קפסולות - temozolomide 250 mg - temozolomide - temozolomide - temodal capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. temodal capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.

Israeli - Kiebrania - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - bcg strain - אבקה להכנת תמיסה להחדרה - bcg strain 200 - 800 miu - bcg vaccine - bcg vaccine - oncotice is used as a treatment of flat urothelial cell carcinoma in situ (cis) of the bladder and as an adjuvant therapy after transurethral resection (tur) of a primary or relapsing superficial papillary urothelial cell carcinoma of the bladder stage ta (grade 2 or 3) or t1 (grade 1 2 or 3). oncotice is only recommended for stage ta grade 1 papillary tumors when there is judged to be a high risk of tumor recurrence.

Israeli - Kiebrania - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Israeli - Kiebrania - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Israeli - Kiebrania - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Israeli - Kiebrania - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - rocuronium bromide - תמיסה להזרקה - rocuronium bromide 10 mg/ml - rocuronium bromide - rocuronium bromide - adjunct to general anaesthesia to facilitate tracheal intubation, to provide skeletal muscle relaxation during surgery. esmeron indicated as an adjunct in the intensive care unit (icu) to facilitate tracheal intubation and mechanical ventilation.

Israeli - Kiebrania - Ministry of Health

padagis israel agencies ltd, israel - paracetamol - קפליות - paracetamol 500 mg - paracetamol - paracetamol - for temporary relief of pain and fever of different etiologics such as: headache, cold, influenza, dysmenorrhea, toothache and minor rheumatic pain.

Israeli - Kiebrania - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - asenapine as maleate - טבליות למתן מתחת ללשון - asenapine as maleate 5 mg - asenapine - asenapine - schizophrenia saphris is indicated for the treatment of schizophrenia in adults. the efficacy of saphris was established in two 6-week trials and one maintenance trial in adults bipolar disorder monotherapy: saphris is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in two 3-week monotherapy trials in adults adjunctive therapy: saphris is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in one 3-week adjunctive trial in adults.

Israeli - Kiebrania - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - asenapine as maleate - טבליות למתן מתחת ללשון - asenapine as maleate 10 mg - asenapine - asenapine - schizophrenia saphris is indicated for the treatment of schizophrenia in adults. the efficacy of saphris was established in two 6-week trials and one maintenance trial in adults bipolar disorder monotherapy: saphris is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in two 3-week monotherapy trials in adults adjunctive therapy: saphris is indicated as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar i disorder. efficacy was established in one 3-week adjunctive trial in adults.

Israeli - Kiebrania - Ministry of Health

padagis israel agencies ltd, israel - dextromethorphan hydrobromide; guaifenesin - סירופ - dextromethorphan hydrobromide 10 mg / 5 ml; guaifenesin 100 mg / 5 ml - dextromethorphan - dextromethorphan - for relief of cough and expecctorant.